ABSTRACT

Introduction Since Andreas Grüntzig described the first percutaneous coronary intervention (PCI) in 1978 (1), the field has progressed immeasurably in both equipment and pharmacotherapy. The overall trend with regard to the latter has been for improved strategies aimed at inhibition of platelet aggregation and the clotting cascade. This has led to better outcomes by reduction of the ischemic complications associated with the procedure.